Story
Biotech Firm Scribe Therapeutics Files for Initial Public Offering on Nasdaq
Summary
Scribe Therapeutics has submitted a registration statement for an initial public offering on the Nasdaq Global Market, planning to trade under the ticker symbol 'SCTX'. The number of shares and offering price have not yet been disclosed.
Biotechnology company Scribe Therapeutics has formally initiated the process to go public, filing a registration statement for an initial public offering (IPO) with U.S. regulators. The company plans to list its common stock on the Nasdaq Global Market under the proposed ticker symbol SCTX.
Filing Details
According to the public filing, the number of shares to be offered and the potential price range for the offering have not yet been determined. The company used placeholder values in its initial registration statement, a common practice in early-stage IPO filings.
Currently, there is no public market for Scribe Therapeutics' common stock. The completion of the IPO is contingent upon the company meeting all of the exchange's listing standards and subsequent market conditions.
AdUnderwriters and Market Context
A consortium of investment banks is managing the offering. Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities are listed as the joint book-running managers for the proposed IPO.
The filing marks a significant step for the company as it seeks to raise capital from public markets to fund its operations and research pipeline. The move will be closely watched by investors in the biotechnology sector, which often relies on significant capital investment for drug development and commercialization.